Vericel (VCEL)

Its sports medicine franchise is led by MACI, an autologous cellularized scaffold product used to repair symptomatic cartilage defects of the knee. MACI is made using a patient’s own cartilage cells, which are expanded and placed on a collagen membrane before implantation by a surgeon. This personalized approach distinguishes Vericel from companies that sell more traditional orthopedic implants or broadly used pharmaceutical products.

In severe burn care, Vericel markets Epicel, a cultured epidermal autograft used for patients with deep dermal or full-thickness burns. Epicel is also an autologous cell-based therapy, produced from a small sample of the patient’s skin and used when extensive burn injuries require specialized coverage. The company also markets NexoBrid, a biologic product used for enzymatic removal of eschar in adults with deep partial-thickness or full-thickness thermal burns.

Vericel operates as a fully integrated company, handling key functions such as research, product development, manufacturing, regulatory support, and commercial distribution. Its business is reported as one segment and is concentrated in the US market. The company’s distinctive position comes from combining cell therapy manufacturing capabilities with targeted commercial franchises in orthopedics and burn treatment, areas that require physician education, specialized hospital relationships, and consistent product quality.